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Abstract
Background: Acinetobacter baumannii can cause serious healthcare-associated infections (HAIs) and the incidence
is increasing, with many strains now resistant to multiple antibiotic classes. The aims of this study were to examine
factors associated with HAIs caused by antimicrobial-resistant as compared with antimicrobial-susceptible strains of
A. baumannii and to investigate trends in the incidence of resistance over time. Electronic data from two U.S.
hospitals in a large urban healthcare system in over the years 2006–2012 were used for the analysis. Multiple
logistic regression was used to explore risk factors for infection with A. baumannii resistant to ampicillin or
ampicillin/sulbactam in the bloodstream, urinary tract, and respiratory tract. The Cochran-Armitage trend test was
used to explore resistance trends over time.
Findings: A total of 671 adults with first-time A. baumannii infection were included in the analysis; 302 isolates
(45 %) were resistant to ampicillin or ampicillin/sulbactam and 369 (55 %) were susceptible. In the multivariable
analysis, significant risk factors included longer length of stay prior to infection (Odds Ratio [OR] = 1.03; 95 %
Confidence Interval [CI]: 1.01, 1.04), hospital A versus B (OR = 0.35; 95 % CI: 0.13, 0.93), and antibiotic use prior to
infection (OR = 2.88; 95 % CI: 1.02, 8.13). Resistance was more common in respiratory infections (OR = 2.96; 95 % CI:
1.04, 8.44). No trend was found between year of infection and resistance.
Conclusions: The risk factors we identified are consistent with previous findings, but we found no evidence in this
population that resistance to ampicillin or ampicillin/sulbactam was increasing over time.
Background
Acinetobacter baumannii is increasingly implicated as a
cause of healthcare-associated infections (HAI), which
confer a high risk of morbidity and mortality to patients
[1–5]. Infections caused by A. baumannii may also be
highly resistant to antimicrobials, particularly those
strains isolated from critically ill patients in intensive
care settings [6–9]. A. baumannii isolates that are resist-
ant to antibiotics can worsen outcomes for patients due
to delays in administration of effective therapy, limited
treatment options, and high toxicity of available therap-
ies [1]. Risk factors for multidrug-resistant A. baumannii
colonization and infection include prolonged length of
hospital stay, exposure to the intensive care unit (ICU),
mechanical ventilation, central venous catheterization,
urinary catheterization, prior exposure to antimicrobials,
greater severity of illness, surgery, and receipt of invasive
procedures [1, 10, 11]. Although risk factors for antibiotic-
resistant A. baumannii infection have been explored in
many patient populations, fewer studies have assessed
potential differences in risk factors for those infected with
antimicrobial-resistant versus susceptible strains.
Antimicrobial resistance among A. baumannii appears
to be on the rise internationally [8, 12], though temporal
changes in antimicrobial susceptibility have not been
widely described and may vary locally. Furthermore, re-
search suggests seasonal variation in A. baumannii inci-
dence [13], yet research into this association is limited.
Therefore, the aims of this study were to examine factors
associated with HAIs caused by antimicrobial-resistant
as compared with antimicrobial-susceptible strains of A.
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baumannii, as well as to investigate trends in the inci-
dence of resistance over time.
Materials and methods
Study population
This retrospective cohort study was conducted as part of
a federally funded project, “Health Information Technol-
ogy to Reduce Healthcare-Associated Infection” (Na-
tional Institute of Nursing Research, National Institutes
of Health; R01NR010822),” which established a clinical
research database of patients hospitalized within a large
urban healthcare system in New York City. This analysis
included all adult (≥18 years) discharges occurring from
2006 to 2012 in two tertiary/quaternary care hospitals
within the system: a 647-bed adult facility and a 914-bed
pediatric/adult facility.
Data collection
The study database was constructed using electronic
data from clinical and administrative systems shared be-
tween the study institutions [14]. The primary outcome
of interest was the first hospital-acquired (i.e., occurring
>2 days after hospital admission) bloodstream infection
(BSI), urinary tract infection (UTI), surgical site infection
(SSI), or pneumonia caused by A. baumannii. Infections
were identified using a combination of time-stamped
microbiology laboratory records and International Clas-
sification of Diseases, Ninth Revision, Clinical Modifica-
tion (ICD-9-CM) procedure and diagnosis codes, based
on modified criteria from the Centers for Disease Con-
trol and Prevention National Healthcare Safety Network
(NHSN) [15]. BSI were defined as positive A. baumannii
blood culture with no positive culture at another body
site within the previous 14 days. UTI were defined as
positive A. baumannii urine culture, i.e., ≥105 colony
forming units (CFU) per mL of urine and no more than
one other species of microorganism, or 103-105 CFU/mL
plus pyuria. SSI were defined as positive A. baumannii
wound culture within 30 days of an ICD-9-CM-documented
NHSN operative procedure. Pneumonia was defined
as positive A. baumannii respiratory culture plus any
ICD-9-CM code for bacterial pneumonia. Resistance
to ampicillin or ampicillin/sulbactam was determined
for each infection based on antibiogram data, which
were stored electronically for all cultures. The year
and season of each infection (Winter, January-March;
Spring, April-June; Summer, July-September; Fall, October-
December) were also recorded.
Patients’ demographic characteristics and medical con-
ditions were collected from electronic sources. The insti-
tution’s electronic medication administration record was
used to determine whether patients received antibiotics or
high risk medications (including chemotherapeutic agents,
immunosuppressants, and anti-inflammatory drugs) at
least 24 h before infection. Comorbidities (diabetes, renal
failure, and malignancies) and the Charlson Comorbidity
Index [16] were collected using ICD-9-CM codes. Elec-
tronic administrative records were used to determine
patients’ age, sex, length of hospitalization, ICU admission,
prior within-network hospitalization, and admission from
a skilled nursing facility.
Statistical analysis
The frequency of BSI, UTI, SSI, and pneumonia caused
by antibiotic sensitive and resistant A. baumannii were
recorded by year. The Cochran-Armitage test for trend
was used to assess whether the proportion of A. bau-
mannii infections that were resistant to antibiotics chan-
ged over time. To explore risk factors for HAI caused by
antimicrobial resistant versus susceptible A. baumannii
strains, bivariate analyses between infection and possible
predictors were conducted using Pearson’s χ2 test for inde-
pendence (categorical variables) or simple logistic regres-
sion (continuous variables). Variables examined included
age, gender, hospital (A or B), ICU stay prior to infection,
Charlson Comorbidity Index, diabetes, renal failure, ma-
lignancy, length of hospital stay prior to infection, anti-
biotic and high-risk medication use prior to infection,
season and year (2006–2012), prior stay in a skilled nurs-
ing facility, prior in-network hospitalization, and infection
site (BSI, UTI, or pneumonia). SSI were excluded from
this analysis due to small sample size. Variables with a
p-value less than 0.25 in the bivariate analysis were
included in a multivariable logistic regression model in
a stepwise forward fashion. All analyses were performed
using SAS version 9.4 (SAS Institute, Cary, NC).
Results
A total of 671 adults with first time hospital-acquired A.
baumannii infection were identified from 2006 through
2012; 302 patients (45 %) had antimicrobial resistant A.
baumannii infections and 369 (55 %) had antimicrobial
susceptible infections. Differences between patients with
antimicrobial resistant versus susceptible A. baumannii
infections are described in Table 1. In the final multivari-
able model, the significant predictors of resistance were
length of stay prior to infection (OR = 1.03; 95 % CI: 1.01,
1.04), being at hospital A vs. B (OR = 0.35; 95 % CI: 0.13,
0.93), having a respiratory infection versus other infection
types (OR = 2.96; 95 % CI: 1.04, 8.44), and antibiotic use
prior to infection (OR = 2.88; 95 % CI: 1.02, 8.13).
Of the total number of first time A. baumannii infec-
tions over the study period from 2006 to 2012, 43-68 %
were due to strains resistant to antibiotics. Although
there were significant differences by year (chi-square test
for independence p = 0.003), there was no significant
trend of increasing or decreasing incidence of resistance
over time (Cochran-Armitage p = 0.73; Fig. 1).
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Discussion
According to the most recent NHSN report, among A.
baumannii infections identified in 2009–10, 78 % of
catheter-associated urinary tract infections, 67 % of
central-line associated bloodstream infections had multi-
drug resistance, and 99 % of ventilator-associated pneu-
monia were multidrug resistant [5]. However, other
studies have reported rates of multidrug resistance be-
tween 51 and 54 % [17, 18], which are closer to the rate
of resistance found in this study (45 %). Estimates of the
prevalence of resistance may vary due to differences in
the definitions of antimicrobial resistance used across
studies, as well as differences in the types of infections
studied, patient case mix, and geographic location.
Seasonality, however, does not appear to play a role.
Although rates of resistance differed by year, there was
no significant trend over time. A previous report from
New York City comparing resistance to ampicillin/sul-
bactam across three time points found an increase be-
tween 1999 and 2001 (34 % to 46 %), though this trend
did not continue into 2006 (44 %) [19]. Other U.S. stud-
ies, however, have reported large increases in resistance
over the past decade. A study conducted in Detroit
found that between 2003 and 2008, the total number of
patients with A. baumannii infection increased, as did
resistance to most antibiotics, with ampicillin/sulbactam
resistance climbing from 11 % to 60 % [20]. NHSN de-
scribed an increase in multidrug resistance covering six
classes including ampicillin/sulbactam from 50 % in
2007–8 to 63 % in 2009–10 [5]. It appears, therefore,
that there is no consistent trend in ampicillin/sulbactam
Table 1 Factors associated with healthcare-associated infection
caused by antimicrobial resistant versus susceptible Acinetobacter
baumannii in two New York City hospitals, 2006-2012
Resistant to ampicillin or ampicillin/
sulbactam
Yes, N (%) No, N (%) P-value*
Total 302 (45 %) 369 (55 %)
Mean (range) age, in years 61 (19–98) 61 (18–97) 0.65
Sex
Female 125 (41 %) 160 (43 %) 0.61
Male 177 (59 %) 209 (57 %)
Hospital
A 217 (76 %) 190 (58 %) <0.0001
B 70 (24 %) 139 (42 %)
ICU prior to infection
Yes 219 (83 %) 178 (82 %) 0.72
No 44 (17 %) 39 (18 %)
Mean (range) Charlson
Comorbidity Index
5.61 (0–17) 5.39 (0–16) 0.40
Mean (range) days of stay
prior to infection
39 (3–377) 18 (3–193) <0.0001
High risk medication
prior to infection
Yes 136 (72 %) 155 (77 %) 0.24
No 53 (28 %) 46 (23 %)
Prior stay in skilled nursing facility
Yes 21 (7 %) 31 (8 %) 0.49
No 281 (93 %) 338 (92 %)
Prior in-network hospitalization
Yes 72 (24 %) 74 (20 %) 0.24
No 230 (76 %) 295 (80 %)
Year of infection onset
2006 32 (11 %) 69 (19 %) 0.003
2007 67 (22 %) 65 (18 %)
2008 64 (21 %) 48 (13 %)
2009 40 (13 %) 52 (14 %)
2010 36 (12 %) 44 (12 %)
2011 41 (14 %) 47 (13 %)
2012 22 (7 %) 44 (12 %)
Site of infection
Bloodstream 65 (22 %) 85 (23 %) 0.64
Urinary tract 96 (32 %) 123 (33 %) 0.67
Pneumonia 187 (62 %) 172 (47 %) <0.0001
Season of infection onset
Winter 67 (22 %) 83 (22 %) 0.75
Spring 76 (25 %) 95 (26 %)
Summer 85 (28 %) 113 (31 %)
Fall 74 (25 %) 78 (21 %)
Table 1 Factors associated with healthcare-associated infection
caused by antimicrobial resistant versus susceptible Acinetobacter
baumannii in two New York City hospitals, 2006-2012 (Continued)
Diabetes
Yes 100 (33 %) 106 (29 %) 0.22
No 202 (67 %) 263 (71 %)
Renal failure
Yes 181 (60 %) 179 (49 %) 0.003
No 121 (40 %) 190 (51 %)
Malignancy
Yes 69 (23 %) 79 (21 %) 0.65
No 233 (77 %) 290 (79 %)
Antibiotic use prior to infection
Yes 16 (40 %) 20 (20 %) 0.017
No 24 (60 %) 78 (80 %)
Numbers in strata may not equal total due to missing values
*Continuous variables assessed using simple logistic regression (Wald χ2).
Categorical variables assessed using Pearson’s χ2
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resistance for A. baumannii, and that trends may be pri-
marily associated with local practices or other regional
differences.
This study identified four risk factors for hospital-
acquired A. baumannii resistant infection. Consistent with
other studies, a longer hospital stay prior to infection, in-
fection in the respiratory tract, and antibiotic use before
infection were all significant predictors of antimicrobial re-
sistance [1, 2, 12]. Greater resistance among respiratory
tract infections may be explained in part by high levels of
A. baumannii contamination on respirators and suctioning
equipment, particularly in ICUs, which may lead to envir-
onmental reservoirs of resistant strains [21]. This finding
highlights the importance of environmental hygiene for
preventing A. baumannii infections in the respiratory tract,
especially for ventilated patients. Unexpectedly, being in
hospital A vs. B was also a significant predictor, controlling
for potential confounders such as comorbidities, medica-
tions used, other host characteristics, and length of stay.
There are no obvious reasons why resistance varied signifi-
cantly between the two hospitals, given that both are ter-
tiary/quaternary care hospitals within the same hospital
system. It is possible that there were other host or environ-
mental factors which were unaccounted for, though this
could not be assessed due to the retrospective nature of
our study. While the infection prevention policies were the
same in both hospitals, it is also possible that infection pre-
vention practices varied [22, 23].
There are some limitations to this study. Firstly, we did
not examine factors associated with resistance among
patients with surgical site infections because the numbers
were too few. Secondly, data were limited to what was
available from electronic data sources. Although the elec-
tronic algorithms used to detect infections are based on
NHSN criteria and have been validated by a clinical team,
the “gold standard” for identifying infections is clinician
diagnosis. In addition, information on the molecular char-
acteristics of A. baumannii isolates were not available, so
subtyping could not be performed. Furthermore, some pa-
tient comorbidities were identified by ICD-9-CM codes,
which have been shown to have poor sensitivity for many
chronic conditions [24]. Lastly, this study was conducted
using data from a single healthcare system in the United
States, a region where A. baumannii is not endemic. Thus
the findings may not be generalizable to other populations.
The results of this study confirm what some other
studies have shown, that the length of hospital stay and
antibiotic use prior to infection are significantly associ-
ated with increased risk of an antimicrobial resistant A.
baumannii infection, and that resistance was more com-
mon in the respiratory tract as compared to other body
sites. Unlike other studies investigating risk factors for
infection, this study also examined trends in resistance
over a seven year period and found no clear pattern in
the prevalence of resistance to ampicillin/sulbactam
among A. baumannii strains.
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Fig. 1 Percent of hospital-acquired Acinetobacter baumannii strains resistant to ampicillin or ampicillin/sulbactam in two New York City hospitals,
2006–2012. Pearson’s χ2 test for independence across years, p = 0.003. Two-sided Cochran-Armitage test for trend, p = 0.73
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